Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp372 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Decreased bone mineral density is associated with coronary atherosclerosis in healthy postmenopausal women

Jo Mihyun , SiHyun Cho , Choi Young Sik , Lee Byung Seok , Seo Seok Kyo

Objective: The aim of this study was to assess the association between bone mineral density (BMD) and coronary atherosclerosis in healthy postmenopausal women.Methods: We performed a retrospective review of 252 postmenopausal women who visited the health promotion center for a routine checkup, after excluding participants who had factors affecting BMD and coronary artery disease. BMD of the lumbar spine and proximal femur was evaluated by dual-energy X-r...

ba0004p179 | (1) | ICCBH2015

An atypical case of bone fragility and dysmorphism with an unusual and novel de novo COL1A1 mutation

Skae Mars , Rauch Frank , Mughal Zulf , Sims Jo , Davis Naomi , Scott B , Arundel Paul , Hobson Emma

We report a male child presenting with antenatally diagnosed bilateral talipes equinovarus, short stature, bilateral cryptorchidism and poor weight gain; born at 39 weeks gestation (birth weight 2.56 kg) to non-consanguineous Caucasian parents. Facial dysmorphism included a prominent forehead, brachycephaly, shallow orbits, a high anterior hairline, a narrow nasal bridge and small mouth with a thin upper lip. He had white sclera and was short for height (−4.4 SDS) with a...

ba0005p201 | Cell biology: osteoclasts and bone resorption | ECTS2016

Galectin-1 is involved in osteoclast biology

Muller Josephine , Binsfeld Marilene , Dubois Sophie , Carmeliet Geert , Beguin Yves , Heusschen Roy , Caers Jo

Osteolytic bone disease (OBD) is a frequent complication of multiple cancers, such as multiple myeloma. OBD is due to the disruption of balanced bone remodelling, with higher bone resorption due to increased osteoclast activation and osteoblast inhibition. Lectin–glycoprotein interactions have been implicated in osteoclast formation. In the current study, we set out to identify lectins that are involved in osteoclastogenesis and to study their role in this process. We ant...

ba0005p123 | Cancer and bone: basic, translational and clinical | ECTS2016

The SRC kinase inhibitor saracatinib limits the development of osteolytic bone disease in multiple myeloma

Heusschen Roy , Muller Josephine , Binsfeld Marilene , Plougonven Erwan , Mahli Nadia , Carmeliet Geert , Leonard Angelique , Cohen-Solal Martine , Vanderkerken Karin , Beguin Yves , Menu Eline , Caers Jo

Destructive bone lesions due to osteolytic bone disease (OBD) are a major cause of morbidity and mortality in multiple myeloma (MM) patients and the development of new therapeutic strategies is of great interest. In this study, we assessed the effect of SRC inhibition with saracatinib (AZD0530, AstraZeneca) on the development of MM and its associated OBD. We first determined SRC family kinase expression in the MM microenvironment and found that myeloma cells express SRC at low...